Johnson & Johnson Launches New Plaque Psoriasis Treatment to Challenge AbbVie’s Skyrizi
AbbVie reported strong Q1 results with its immunology drug Skyrizi as a key growth driver. Johnson & Johnson recently launched Icotyde, an oral treatment for plaque psoriasis that could compete directly with Skyrizi. However, analysts suggest Skyrizi's efficacy may still give it the edge despite administration preferences.
Topics: AbbVie Icotyde Johnson & Johnson plaque psoriasis Skyrizi